YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Ipsen Pharma Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the…
Ipsen Pharma Aggregatedpresentationbydayandbymarket Weekly report on share repurchases from 21st September to 22nd September 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Tota…
Ipsen (ENXTPA:IPN) has refreshed its governance, with the board appointing Mariette Finet as Director and member of the Board Portfolio Committee following Michèle Ollier's resignation earlier in the summer. Ipsen's share price has softene…
Ipsen Pharma Aggregatedpresentationbydayandbymarket Weekly report on share repurchases from 14th September to 18th September 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Tota…
Ipsen Pharma Ipsen appoints Mariette Finet to its Board of Directors PARIS, FRANCE, 18 SEPTEMBER 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Mariette Finet as a Director to its Board of Directors, effective…
Ipsen Pharma Aggregatedpresentationbydayandbymarket Weekly report on share repurchases from 31st August to 04th September 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total d…
Ipsen Pharma Aggregatedpresentationbydayandbymarket Weekly report on share repurchases from 7th September to 11th September 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ipsen stock has more than doubled over the past five years, yet the latest valuation checks send mixed signals. The Discount…
[bad day at wall street] franckreporter * Bank of America Securities has initiated coverage of ProQR Therapeutics (PRQR [https://seekingalpha.com/symbol/PRQR]) at buy, saying that the company's Axiomer RNA-editing platform has been validat…
Ipsen Pharma Aggregated presentation by day and by market Weekly report on share repurchases from 04th August to 05th August 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Tota…
This article first appeared on GuruFocus. Total Revenues: Approximately $629 million for Q2 2026. Cabozantinib Franchise Net Product Revenues (US): $573 million, up approximately 10% year-over-year. Global Cabozantinib Franchise Net Produc…
Ipsen Pharma Aggregated presentation by day and by market Weekly report on share repurchases from 27th July to 31st July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total da…
IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large Jarrett Banks in a video session lasti…
This article first appeared on GuruFocus. Release Date: July 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Total sales grew 23.5% at constant exchange rates, w…
Investing.com -- Shares in French drugmaker Ipsen SA slippedon Thursday even as the company's second-quarter product sales of €1,115 million beat company-compiled consensus of €1,048 million by 6%, or €67 million, helped by strong Somatuli…
Ipsen Pharma H1 2026 results with sales growth of 23.5% at CER1, or 20.4% as reported, with the portfolio beyond Somatuline® achieving sales growth of 24.8%1 and core operating income of €845m, growing by 28.8% as reported, with a core ope…
Ipsen Pharma Ipsen appoints Catherine Bradley as independent Director to its Board of Directors PARIS, FRANCE, 29 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Catherine Bradley, CBE, as an independent Di…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Ipsen stock has delivered an 85.4% return over the past 5 years, yet the valuation picture is split, with the Discounte…
Ipsen Pharma Aggregated presentation by day and by market Weekly report on share repurchases from 20th July to 24th July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total da…
Ipsen Pharma PARIS, FRANCE, 24 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III BOLD trial evaluating Bylvay versus placebo for patients living with biliary atresia (BA) who have already undergone a Kasai he…
PARIS, FRANCE, 24 JUILLET 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) a annoncé aujourd’hui que l'essai de Phase III BOLD, évaluant Bylvay versus placebo chez des patients atteints d'atrésie des voies biliaires (AVB) ayant déjà subi une hépat…
Ipsen Pharma CORRECTIVE STATEMENT Corrective statement amending the monthly disclosure of the total number of shares and voting rights as of June 30, 2026, published on July 9, 2026 Paris, July 22, 2026 This corrective statement is issued…
Ipsen Pharma PARIS, FRANCE, 22 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal a…
PARIS, FRANCE, 22 JUILLET 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) a annoncé aujourd'hui avoir finalisé l'acquisition de Memo Therapeutics AG - une société de biotechnologie en phase avancée de développement - portant sur le potravitug, un…
PARIS, FRANCE, 22 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody. Abou…
Ipsen Pharma Aggregated presentation by day and by market Weekly report on share repurchases from 13th July to 17th July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total da…
Ipsen Pharma Aggregated presentation by day and by market Weekly report on share repurchases from 6th to 10th July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily vo…
BioCryst Pharmaceuticals, Inc. RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) ("BioCryst" or the "Company") today announced the appointment of David W. Jenkins, MA, PhD, to the…
Ipsen Pharma Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the…
Ipsen Pharma Dysport® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) migraine Dysport is the first botulinum toxin in episodic migraine to demonstrat…
Dysport® a obtenu des résultats préliminaires statistiquement significatifs de phase III, atteignant les critères d’évaluation principaux dans la migraine épisodique (E-BEOND) et dans la migraine chronique (C-BEOND)Dysport est la première…
Dysport® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) migraineDysport is the first botulinum toxin in episodic migraine to demonstrate a statistica…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ipsen has delivered a 100.7% total return over the past five years, yet there is a clear split in what the valuation work is…
Ipsen Pharma Half-year statement of the liquidity agreement between IPSEN SA and NATIXIS ODDO BHF PARIS, 07 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that under the liquidity agreement entrusted by IPSEN S.A. to NATIXIS…
Ipsen Pharma Aggregated presentation by day and by market Weekly report on share repurchases from 30th June to 03rd July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total da…
Ipsen Pharma Aggregated presentation by day and by market Purchases of own shares from June 22nd to June 26th 2026 Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total daily…